Results 201 to 210 of about 212,106 (307)

Correction: Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges

Yoshiharu Sato
openalex   +1 more source

Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide

, 1990
Tomasz Skórski, Maciej Kawalec, J Kawiak   +2 more
openalex   +2 more sources

Hands‐on protocol for preparing water‐soluble fractions from agri‐food samples for NMR‐based metabolomics analysis

FEBS Open Bio, EarlyView.
This research protocol outlines a workflow for nuclear magnetic resonance (NMR)‐based metabolomics in the agri‐food sector. Using two case studies—strawberry leaves (solid matrix) and wine (liquid matrix)—it details the procedures for sample preparation, data acquisition, and processing.
Andrea Fernández‐Veloso, Jaime Hiniesta‐Valero, Alejandra Guerra‐Castellano, Miguel A. De la Rosa, Irene Díaz‐Moreno   +4 more
wiley   +1 more source

Correction to: Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma. [PDF]

Ann Hematol
Yang Y, Zhang X, Jiang N, Jin Y, Liu Y, Liao H.   +5 more
europepmc   +1 more source

Minimal Residual Disease Relapse [PDF]

, 2020
openaire   +1 more source

Antibiofilm activity of a chionodracine‐derived peptide by NMR‐based metabolomics of cell‐free supernatant of Acinetobacter baumannii clinical strains

FEBS Open Bio, EarlyView.
KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli, Enrico Landi, Francesco Maiurano, Irene Paris, Rosanna Papa, Marco Artini, Laura Selan, Stefano Borocci, Francesco Buonocore, Esther Imperlini   +9 more
wiley   +1 more source

Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma. [PDF]

Sci Rep
Bauer F, Hajiyianni M, Weinhold N, Grözinger M, Kächele J, Menis E, Raab MS, Sauer S, Jauch A, Weber TF, Debic M, Besemer B, Horger M, Afat S, Hoffmann M, Hoffend J, Kraemer D, Graeven U, Ringelstein A, Dürig J, Umutlu L, Schlemmer HP, Goldschmidt H, Maier-Hein K, Delorme S, Mai EK, Wennmann M, Neher P.   +27 more
europepmc   +1 more source

Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease

, 2005
Steven J. Oosterling, Gerben J. van der Bij, Marijn Bögels, Joost R.M. van der Sijp, R.H.J. Beelen, S. Meijer, Marjolein van Egmond   +6 more
openalex   +2 more sources

Pathogenic Neurofibromatosis type 1 gene variants in tumors of non‐NF1 patients and role of R1276

FEBS Open Bio, EarlyView.
Somatic variants of the neurofibromatosis type 1 (NF1) gene occur across neoplasms without clinical manifestation of the disease NF1. We identified emerging somatic pathogenic NF1 variants and hotspots, for example, at the arginine finger 1276. Those missense variants provide fundamental information about neurofibromin's role in cancer.
Mareike Selig, Swanhild Lohse, Sara Elahi, Nils Hartmann, Stefanie Deckert, Shutian Si, Alexander Desuki, Anja Harder   +7 more
wiley   +1 more source

Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors. [PDF]

Int J Mol Sci
Nikitsenka K, Danieli G, Tombolan L, Mancini B, Facchinelli D, Scotton G, Tosetto A, Perbellini O, Zuccarello D, Novella E.   +9 more
europepmc   +1 more source